Gihon Biotech Limited, founded by Professor Zhang Hongjie, Associate Dean (Teaching and Learning) and Chair Professor of Chinese Medicine, has received official registration from the National Medical Products Administration (NMPA) of China for its patented natural stilbenoid compound, dihydro-resveratrol (DR2), as a new cosmetic ingredient (Registration No.: 国妆原备字20250102). This marks the first-ever NMPA approval granted to a Hong Kong-based entity for a new cosmetic ingredient, paving the way for the official manufacture and commercialisation of DR2-based cosmetic and skincare products in Mainland China.

DR2, developed by Professor Zhang’s research team, is extracted from the Chinese medicinal herb Dendrobium (Dendrobium officinale and Dendrobium nobile).  As a bioactive metabolite of resveratrol, DR2 offers enhanced safety, bioavailability and absorption. Research has demonstrated its efficacy in skin whitening and anti-ageing, primarily through inhibiting tyrosinase in the melanin production. Its compatibility with both water- and oil-based formulations enables broad application across skincare and cosmetic products. This compound has already been patented in China, the United States, Japan, Singapore, Malaysia, Taiwan, and Hong Kong.

Professor Zhang shared his enthusiasm on the approval and commented, “This recognition affirms the safety and potential of DR2, and lays a strong foundation for our entry into the China market. We will continue to accelerate research and translate our discoveries into practical applications.”

Traditional Chinese herbs are rich in bioactive compounds with proven therapeutic value. The School encourages continued exploration of these natural resources to translate their medicinal potential, advance the modernisation of Chinese medicine and showcase Hong Kong’s scientific innovations globally, ultimately contributing to the health and beauty worldwide.